Low prevalence of obesity in Behçet's disease is associated with high obestatin level

dönder, emir; Ilhan, Nevin; AKSOY, Kader; KARA, MURAT; Ozgen, Metin; Koca, Suleyman Serdar; DEMİR, Caner Feyzi; DAYANAN, Ramazan; IŞIK, Ahmet

Low prevalence of obesity in Behçet's disease is associated with high obestatin level

Süleyman Serdar KOCA, (Fırat Üniversitesi, Tıp Fakültesi, Romatoloji Anabilim Dalı, Elazığ, Türkiye)

Murat KARA, (Muğla Sıtkı Koçman Üniversitesi, Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, Muğla, Türkiye)

Metin ÖZGEN, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Romatoloji Bilim Dalı, Samsun, Türkiye)

Ramazan DAYANAN, (Fırat Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Elazığ, Türkiye)

Caner Feyzi DEMİR, (Fırat Üniversitesi, Tıp Fakültesi, Nöroloji Anabilim Dalı, Elazığ, Türkiye)

Kader AKSOY, (Fırat Üniversitesi, Tıp Fakültesi, Endokrinoloji Anabilim Dalı, Elazığ, Türkiye)

Nevin İLHAN, (Fırat Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Elazığ, Türkiye)

Emir DÖNDER, (Fırat Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Elazığ, Türkiye)

Ahmet IŞIK (Fırat Üniversitesi, Tıp Fakültesi, Romatoloji Anabilim Dalı, Elazığ, Türkiye)

European Journal of Rheumatology

2 0

Yıl: 2017 Cilt: 4 Sayı: 2 Sayfa Aralığı: 113 - 117 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Low prevalence of obesity in Behçet's disease is associated with high obestatin level

Öz:

Objective: Chronic inflammatory diseases are associated with altered body composition. Ghrelin has anti-inflammatory effects, and its level is altered in obesity and inflammatory diseases. The aim of the study was to evaluate the prevalence of obesity and ghrelin and obestatin levels in patients with Behçet's disease (BD). Material and Methods: One hundred and forty-three (143) patients with BD and 112 healthy controls (HC) were enrolled. Participants were subdivided according to the body mass index (BMI) as lean (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2) and obese (>=30 kg/m2). In addition to the routine evaluations (fasting blood glucose, lipid profile, and kidney and liver function tests), serum acylated-ghrelin (AG), unacylated-ghrelin (UAG), total ghrelin (TG) and obestatin levels were analyzed. Student's t-test and chi-square test were used for statistical analysis. Results: The prevalence of obesity was relatively lower in the BD group than in the HC group (12.6% vs. 20.5%, p=0.089). Serum ghrelin levels were similar in the BD and HC groups (p>0.05 for all) although the obestatin level was higher in the BD group compared to the HC group (p<0.001). Serum UAG, TG and obestatin levels were lower in obese BD patients (n=18) than non-obese BD patients (p=0.027, p=0.014 and p=0.001, respectively). Conclusion: The obestatin level was high and the prevalence of obesity was low in the BD group. Moreover, obese BD patients had low obestatin levels. These results suggest that obestatin may protect BD patients from obesity.

Anahtar Kelime:

Konular: Romatoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syn- drome. Endocrine 2006; 29: 109-17. [CrossRef ]
Leite-Moreira AF, Soares JB. Physiological, pathological and potential therapeutic roles of ghrelin. Drug Discov Today 2007; 12: 276-88. [CrossRef ]
Patterson M, Bloom SR, Gardiner JV. Ghrelin and appetite control in humans--potential applica- tion in the treatment of obesity. Peptides 2011; 32: 2290-4. [CrossRef ]
Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric by- pass surgery. N Engl J Med 2002; 346: 1623-30. [CrossRef ]
Otto B, Cuntz U, Fruehauf E, Wawarta R, Fol- waczny C, Riepl RL, et al. Weight gain decreases elevated plasma ghrelin concentrations of pa- tients with anorexia nervosa. Eur J Endocrinol 2001; 145: 669-73.
Lacquaniti A, Donato V, Chirico V, Buemi A, Buemi M. Obestatin: an interesting but contro- versial gut hormone. Ann Nutr Metab 2011; 59: 193-9. [CrossRef ]
Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, et al. Ghrelin in- hibits leptin- and activation-induced proin- flammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114: 57-66. [CrossRef ]
Xia Q, Pang W, Pan H, Zheng Y, Kang JS, Zhu SG. Effects of ghrelin on the proliferation and se- cretion of splenic T lymphocytes in mice. Regul Pept 2004; 122: 173-8. [CrossRef ]
Otero M, Nogueiras R, Lago F, Dieguez C, Go- mez-Reino JJ, Gualillo O. Chronic inflamma- tion modulates ghrelin levels in humans and rats. Rheumatology (Oxford) 2004; 43: 306-10. [CrossRef ]
Koca SS, Ozgen M, Aydin S, Dag S, Evren B, Isik A. Ghrelin and obestatin levels in rheumatoid ar- thritis. Inflammation 2008; 31: 329-5. [CrossRef ]
Magiera M, Kopec-Medrek M, Widuchowska M, Kotulska A, Dziewit T, Ziaja D, et al. Serum ghrelin in female patients with rheumatoid ar- thritis during treatment with infliximab. Rheu- matol Int 2013; 33: 1611-3. [CrossRef ]
Verity DH, Marr JE, Ohno S, Wallace GR, Stan- ford MR. Behçet's disease, the Silk Road and HLA-B51: historical and geographical per- spectives. Tissue Antigens 1999; 54: 213-20. [CrossRef ]
Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet's disease. Autoimmun Rev 2012; 11: 687-98. [CrossRef ]
Stavropoulos-Kalinoglou A, Metsios GS, Koute- dakis Y, Nevill AM, Douglas KM, Jamurtas A, et al. Redefining overweight and obesity in rheu- matoid arthritis patients. Ann Rheum Dis 2007; 66: 1316-21. [CrossRef ]
Elkan AC, Engvall IL, Cederholm T, Hafstrom I. Rheumatoid cachexia, central obesity and malnutrition in patients with low-active rheu- matoid arthritis: feasibility of anthropometry, mini nutritional assessment and body compo- sition techniques. Eur J Nutr 2009; 48: 315-22. [CrossRef ]
Zonana-Nacach A, Santana-Sahagun E, Jimenez-Balderas FJ, Camargo-Coronel A. Prevalence and factors associated with met- abolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol 2008; 14: 74-7. [CrossRef ]
Stavropoulos-Kalinoglou A, Metsios GS, Koute- dakis Y, Kitas GD. Obesity in rheumatoid arthri- tis. Rheumatology (Oxford) 2011; 50: 450-62. [CrossRef ]
Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM. Obesity is an independent contributor to functional capacity and inflammation in sys- temic lupus erythematosus. Arthritis Rheum 2005; 52: 3651-9. [CrossRef ]
Chaiamnuay S, Bertoli AM, Fernández M, Apte M, Vilá LM, Reveille JD, et al. The impact of in- creased body mass index on systemic lupus er- ythematosus: data from LUMINA, a multiethnic cohort (LUMINA XLVI) [corrected]. J Clin Rheu- matol 2007; 13: 128-33. [CrossRef ]
Pandey A, Garg J, Krishnamoorthy P, Pala- niswamy C, Doshi J, Lanier G, et al. Predictors of coronary artery disease in patients with Behçet's disease. Cardiology 2014; 129: 203-6. [CrossRef ]
Yalçın B, Gür G, Artüz F, Allı N. Prevalence of met- abolic syndrome in Behçet disease: a case-con- trol study in Turkey. Am J Clin Dermatol 2013; 14: 421-5. [CrossRef ]
The International Study Group for Behcet's dis- ease. Evaluation of diagnostic ('classification') criteria in Behcet's disease--towards interna- tionally agreed criteria. Br J Rheumatol 1992; 31: 299-308. [CrossRef ]
World Health Organisation. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii: 1-253.
Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet's disease. Autoimmun Rev 2012; 11: 699-704. [CrossRef ]
Özkan Y, Dönder E, Baydaş G, Doğan H, İlhan N, Açık Y. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance among > 30 years of age in an urban community of Elazığ. Biomed Res 1999; 10: 181-9.
Karagiozoglou-Lampoudi T, Trachana M, Aga- kidis C, Pratsidou-Gertsi P, Taparkou A, Lampou- di S, et al. Ghrelin levels in patients with juve- nile idiopathic arthritis: relation to anti-tumor necrosis factor treatment and disease activity. Metabolism 2011; 60: 1359-62. [CrossRef ]
Kim HA, Choi GS, Jeon JY, Yoon JM, Sung JM, Suh CH. Leptin and ghrelin in Korean system- ic lupus erythematosus. Lupus 2010; 19: 170-4. [CrossRef ]
Yilmaz H, Gerdan V, Kozaci D, Solmaz D, Akar S, Can G, et al. Ghrelin and adipokines as circulat- ing markers of disease activity in patients with Takayasu arteritis. Arthritis Res Ther 2012; 14: R272. [CrossRef ]
Toussirot E, Gaugler B, Bouhaddi M, Nguyen NU, Saas P, Dumoulin G. Elevated adiponectin serum levels in women with systemic autoim- mune diseases. Mediators Inflamm 2010; 2010: 938408. [CrossRef ]
Koc F, Kayaoglu HA, Celik A, Altunkas F, Karay- akali M, Ozbek K, et al. Effect of weight loss induced by intragastric balloon therapy on cardiac function in morbidly obese individuals: A pilot study. Med Princ Pract 2015; 24: 432-5. [CrossRef ]
Babusik P, Duris I. Comparison of obesity and its relationship to some metabolic risk factors of atherosclerosis in Arabs and South Asians in Kuwait. Med Princ Pract 2010; 19: 275-80. [CrossRef ]
Zhang M, Fang W, Yuan F, Qu X, Liu H, Chen H, et al. Plasma ghrelin levels are closely associated with stenosis severity and morphology of angi- ographically-detected coronary atherosclerosis in patients with coronary artery disease. Int J Cardiol 2011; 151: 122-3. [CrossRef ]
Seyahi E, Ugurlu S, Cumali R, Balci H, Ozdemir O, Melikoglu M, et al. Atherosclerosis in Behçet's Syndrome. Semin Arthritis Rheum 2008; 38: 1-12. [CrossRef ]
Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, et al. Obestatin, a peptide en- coded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310: 996-9. [CrossRef ]
Sibilia V, Bresciani E, Lattuada N, Rapetti D, Lo- catelli V, De Luca V, et al. Intracerebroventricular acute and chronic administration of obestatin minimally affect food intake but not weight gain in the rat. J Endocrinol Invest 2006; 29: RC31-4. [CrossRef ]
Zizzari P, Longchamps R, Epelbaum J, Blu- et-Pajot MT. Obestatin partially affects ghrelin stimulation of food intake and GH secretion in rodents. Endocrinology 2007; 148: 1648-53. [CrossRef ]
Xing YX, Yang L, Kuang HY, Gao XY, Liu HL. Func- tion of obestatin in the digestive system. Nutri- tion 2017; 34: 21-8. [CrossRef ]
Dembinski A, Warzecha Z, Ceranowicz P, Ciesz- kowski J, Dembinski M, Ptak-Belowska A, et al. Administration of obestatin accelerates the healing of chronic gastric ulcers in rats. Med Sci Monit 2011; 17: BR196-200. [CrossRef ]
Şen LS, Karakoyun B, Yeğen C, Akkiprik M, Yüksel M, Ercan F, et al. Treatment with either obes- tatin or ghrelin attenuates mesenteric isch- emia-reperfusion-induced oxidative injury of the ileum and the remote organ lung. Peptides 2015; 71: 8-19. [CrossRef ]
Beberashvili I, Sinuani I, Azar A, Kadoshi H, Sha- piro G, Feldman L, et al. Low serum concentra- tion of obestatin as a predictor of mortality in maintenance hemodialysis patients. Biomed Res Int 2013; 2013: 796586.[CrossRef ]

APA	Koca S, KARA M, Ozgen M, DAYANAN R, DEMİR C, AKSOY K, Ilhan N, dönder e, IŞIK A (2017). Low prevalence of obesity in Behçet's disease is associated with high obestatin level. , 113 - 117.
Chicago	Koca Suleyman Serdar,KARA MURAT,Ozgen Metin,DAYANAN Ramazan,DEMİR Caner Feyzi,AKSOY Kader,Ilhan Nevin,dönder emir,IŞIK Ahmet Low prevalence of obesity in Behçet's disease is associated with high obestatin level. (2017): 113 - 117.
MLA	Koca Suleyman Serdar,KARA MURAT,Ozgen Metin,DAYANAN Ramazan,DEMİR Caner Feyzi,AKSOY Kader,Ilhan Nevin,dönder emir,IŞIK Ahmet Low prevalence of obesity in Behçet's disease is associated with high obestatin level. , 2017, ss.113 - 117.
AMA	Koca S,KARA M,Ozgen M,DAYANAN R,DEMİR C,AKSOY K,Ilhan N,dönder e,IŞIK A Low prevalence of obesity in Behçet's disease is associated with high obestatin level. . 2017; 113 - 117.
Vancouver	Koca S,KARA M,Ozgen M,DAYANAN R,DEMİR C,AKSOY K,Ilhan N,dönder e,IŞIK A Low prevalence of obesity in Behçet's disease is associated with high obestatin level. . 2017; 113 - 117.
IEEE	Koca S,KARA M,Ozgen M,DAYANAN R,DEMİR C,AKSOY K,Ilhan N,dönder e,IŞIK A "Low prevalence of obesity in Behçet's disease is associated with high obestatin level." , ss.113 - 117, 2017.
ISNAD	Koca, Suleyman Serdar vd. "Low prevalence of obesity in Behçet's disease is associated with high obestatin level". (2017), 113-117.

APA	Koca S, KARA M, Ozgen M, DAYANAN R, DEMİR C, AKSOY K, Ilhan N, dönder e, IŞIK A (2017). Low prevalence of obesity in Behçet's disease is associated with high obestatin level. European Journal of Rheumatology, 4(2), 113 - 117.
Chicago	Koca Suleyman Serdar,KARA MURAT,Ozgen Metin,DAYANAN Ramazan,DEMİR Caner Feyzi,AKSOY Kader,Ilhan Nevin,dönder emir,IŞIK Ahmet Low prevalence of obesity in Behçet's disease is associated with high obestatin level. European Journal of Rheumatology 4, no.2 (2017): 113 - 117.
MLA	Koca Suleyman Serdar,KARA MURAT,Ozgen Metin,DAYANAN Ramazan,DEMİR Caner Feyzi,AKSOY Kader,Ilhan Nevin,dönder emir,IŞIK Ahmet Low prevalence of obesity in Behçet's disease is associated with high obestatin level. European Journal of Rheumatology, vol.4, no.2, 2017, ss.113 - 117.
AMA	Koca S,KARA M,Ozgen M,DAYANAN R,DEMİR C,AKSOY K,Ilhan N,dönder e,IŞIK A Low prevalence of obesity in Behçet's disease is associated with high obestatin level. European Journal of Rheumatology. 2017; 4(2): 113 - 117.
Vancouver	Koca S,KARA M,Ozgen M,DAYANAN R,DEMİR C,AKSOY K,Ilhan N,dönder e,IŞIK A Low prevalence of obesity in Behçet's disease is associated with high obestatin level. European Journal of Rheumatology. 2017; 4(2): 113 - 117.
IEEE	Koca S,KARA M,Ozgen M,DAYANAN R,DEMİR C,AKSOY K,Ilhan N,dönder e,IŞIK A "Low prevalence of obesity in Behçet's disease is associated with high obestatin level." European Journal of Rheumatology, 4, ss.113 - 117, 2017.
ISNAD	Koca, Suleyman Serdar vd. "Low prevalence of obesity in Behçet's disease is associated with high obestatin level". European Journal of Rheumatology 4/2 (2017), 113-117.